Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
Lusvertikimab (OSE-127)
Pegrizeprument (FR104)
BI 770371
ABBV-230
CLEC-1
Research & Development
Scientific publications
Investors
Press Releases
Letter to Shareholders
Newsletters
Q & A
Financial documents
General Shareholders’ meetings
Regulated information
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Our videos
Agenda
Press Releases
Contact
en
fr
Retour aux communiqués
Date
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
Téléchargez